Matthew Taylor

Assistant Professor

  • 4415 Citations
  • 16 h-Index
20102020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Matthew Taylor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 4415 Citations
  • 16 h-Index
  • 30 Article
  • 1 Comment/debate
  • 1 Review article

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

Naing, A., Gainor, J. F., Gelderblom, H., Forde, P. M., Butler, M. O., Lin, C. C., Sharma, S., Ochoa De Olza, M., Varga, A., Taylor, M., Schellens, J. H. M., Wu, H., Sun, H., Silva, A. P., Faris, J., Mataraza, J., Cameron, S. & Bauer, T. M., Mar 15 2020, In : Journal for immunotherapy of cancer. 8, 1, e000530.

Research output: Contribution to journalArticle

Open Access
  • 1 Scopus citations

    A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies

    Taylor, M. H., Alva, A. S., Larson, T., Szpakowski, S., Purkaystha, D., Amin, A., Karpiak, L. & Piha-Paul, S. A., Apr 1 2020, In : Oncotarget. 11, 14, p. 1235-1243 9 p.

    Research output: Contribution to journalArticle

    Open Access
  • Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

    Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., Salvagni, S., Taylor, M., Amin, A., Camidge, D. R., Horn, L., Calvo, E., Li, A., Lin, W. H., Callahan, M. K. & Spigel, D. R., Mar 2020, In : Journal of Thoracic Oncology. 15, 3, p. 426-435 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 9 Scopus citations

    Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

    Ansell, S. M., Flinn, I., Taylor, M. H., Sikic, B. I., Brody, J., Nemunaitis, J., Feldman, A., Hawthorne, T. R., Rawls, T., Keler, T. & Yellin, M. J., May 12 2020, In : Blood Advances. 4, 9, p. 1917-1926 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial

    Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for immunotherapy of cancer. 7, 1, 12.

    Research output: Contribution to journalArticle

  • 8 Scopus citations